glp-1 employer coverage news october 2025 Employers across America are dropping weight-loss drug as costs explode, leaving employees to choose between health and finances. Read more below Big policy shift in obesity

This product may not be used as a pharmaceutical or veterinary drug, agricultural product, or food additive

Approximately a third of patients with frequent PVCs develop cardiomyopathy

Looking ahead, Peptide Centre is committed to expanding our offerings, improving our services, and continuing to build long-lasting relationships with researchers and institutions worldwide

Semaglutide is a GLP-1 agonist currently used to treat type 2 diabetes and for weight management via subcutaneous injection or taken orally

He described the current environment as a prisoners dilemma: one in which cooperation from all parties is required to fully realize the long-term benefits of obesity treatment, but some individual employers still feel they have incentives to delay action

In a review of studies involving 1604 individuals with metabolic syndromes and related disorders, curcumin intake significantly reduced BMI, weight and waist-circumference (2)(3)